New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company have announced new data(1) from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D). The result showed that linagliptin as monotherapy or in initial combination with metformin achieved clinically significant improvements in glucose control in patients with newly diagnosed T2D and marked hyperglycaemia.
Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA.
Novartis Foundation launches new leprosy strategy at symposium on disease elimination
- Details
- Category: Novartis
Today's symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss "What does it take to eliminate a disease?" Drawing lessons from previous successful disease control programs, the symposium speakers discuss innovative approaches and advocate for new coordination strategies in disease elimination efforts.
GSK responds to FDA decision on Avandia (rosiglitazone)
- Details
- Category: GlaxoSmithKline
GSK plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee review in June 2013. GSK welcomes the decision of the FDA and appreciates the Agency's robust review of the science with regard to Avandia.
Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
- Details
- Category: Novartis
Novartis has announced the launch of a USD 5 billion share buyback, reflecting the company's confidence in its long-term growth prospects, as well as its commitment to deliver strong shareholder returns. The buyback will start immediately and be executed over two years on the 2nd trading line.
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (also referred to as Q-Pan H5N1 influenza vaccine) for the immunisation of adults 18 and older for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine.
Pfizer and GSK to initiate study of novel combination therapy in patients with melanoma
- Details
- Category: Pfizer
Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib (GSK1120212) combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.
More Pharma News ...
- Bayer CEO Marijn Dekkers calls for greater appreciation of innovation
- Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children
- Bristol-Myers Squibb Foundation marks World Diabetes Day with four grants addressing link between diabetes, depression and distress
- Experience a day in the life of an insulin-using patient with diabetes through interactive infographic
- Novartis announces positive clinical trial results for novel H7N9 vaccine
- Bristol-Myers Squibb announces changes in its senior management team
- Merck Serono announces five-year strategic partnership with the Lead Discovery Center